New antibody drug aims to wipe out hidden leukemia cells
NCT ID NCT05285813
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tests an experimental drug called vibecotamab in 42 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer did not fully respond to standard treatments. The drug is designed to help the immune system find and destroy remaining cancer cells. The main goal is to see if the drug can make these patients cancer-free at the microscopic level.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.